IP Library Granted Patent US 11,203,739
Granted Patent B2
US 11,203,739 · App. 15/302,560 · Granted Dec 21, 2021

Modulating cell proliferation and pluripotency

Inventors: Lydia W. S. Finley (New York, NY); Bryce W. Carey (New York, NY); Craig B. Thompson (New York, NY); C. David Allis (New York, NY)
Assignees: Memorial Sloan-Kettering Cancer Center; The Rockefeller University
C12N5/0606A61K31/194C12N5/0696C12N2500/30C12N2501/727
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,203,739
App. No.
15/302,560
Granted
Dec 21, 2021
Kind
B2
Abstract

Disclosed herein are compositions, systems, and methods for modulating proliferation, differentiation and pluripotency of cells.

Claims (9)

1. A method for enriching a population of cells for human or mouse pluripotent stem cells, the method comprising steps of:

a) providing a population of cells comprising a mixture of pluripotent stem cells and non-pluripotent cells, wherein the pluripotent stem cells are human or mouse pluripotent stem cells; and

b) culturing the population of cells comprising the mixture of pluripotent stem cells and non-pluripotent cells in a culture medium substantially free of glutamine, wherein the culture medium comprises 0.5 mM-4 mM of cell-permeable dimethyl-α-ketoglutarate (αKG), a mitogen activated protein kinase (MAPK) inhibitor and/or a glycogen synthase kinase 3β (GSKβ) inhibitor;

wherein the pluripotent stem cells have a higher proliferation rate and/or survival rate compared to the non-pluripotent cells during said culturing, thereby producing a population in which pluripotent stem cells are enriched relative to non-pluripotent cells as compared to the provided population of cells.

2. The method of claim 1 , wherein the medium comprises the mitogen activated protein kinase (MAPK) inhibitor and the glycogen synthase kinase 3β (GSK3β) inhibitor.

3. The method of claim 1 , wherein the pluripotent stem cells are embryonic stem cells.

4. The method of claim 1 , wherein the pluripotent stem cells are induced pluripotent stem cells.

5. The method of claim 1 , wherein the provided population of cells comprises an ex vivo population of cells.

6. The method of claim 1 , wherein the produced population comprises at least 60% human or mouse pluripotent stem cells.

Assignments (3)
CONFIRMATORY LICENSE Recorded Dec 14, 2022
From: SLOAN-KETTERING INST CAN RESEARCH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 062121/0657 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2016
From: FINLEY, LYDIA W.S.; THOMPSON, CRAIG B.
To: MEMORIAL SLOAN KETTERING CANCER CENTER
Reel/Frame 040103/0592 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2016
From: CAREY, BRYCE W.; ALLIS, C. DAVID
To: THE ROCKEFELLER UNIVERSITY
Reel/Frame 040103/0614 →
Continuity (3)
Provisional Application 62066294 · Oct 20, 2014
Provisional Application 61976488 · Apr 7, 2014
Related Publication 20170022475A1 · Jan 26, 2017